Early Switch to Atezolizumab After Vemurafenib/Cobimetinib Run-in Shows Improved Survival Trend in Melanoma
Source: Oncology Nursing News, September 2024
Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF V600–positive melanoma.
Patients with BRAF V600–positive melanoma demonstrated a trend toward improved survival at 4 and 5 months with an earlier switch to atezolizumab (Tecentriq) after run-in with vemurafenib (Zelboraf) plus cobimetinib (Cotellic). However, the improvement was not statistically significant, according to long-term data from the phase 2 ImmunoCobiVem trial (NCT02902029) presented at the 2024 European Society for Medical Oncology Congress.
“Yet, a relevant number of patients experienced rapid progression after early switch from targeted therapy to immune checkpoint inhibition [ICI],” Dirk Schadendorf, MD, of theUniversity of Essen and the German Cancer Consortium, Partner Site, in Essen, Germany, said in a presentation of the data.“The better early tumor control—PFS1—with continuous targeted therapy in arm A and treatment options outside the trial influence the overall effect size for early switch from targeted therapy to ICI within this trial.”